you, Thank James.
On side, product start with let’s ANNOVERA. the
on see can on Slide sequential and you X, basis ANNOVERA showed year-over-year. continued As a quarter growth both
procedure-free and quarter good making as the progress ANNOVERA of only this sequential The uptake. XX% growth positioning is trend. product are driving illustrates positive long-lasting this We
XX%. strong behind and growth trajectory. of sequential main quarter revenue refill drivers net remain at steady couple at Our the per unit a $X,XXX about There are held rates
ANNOVERA, again, XX% to to targets live for even the we lead if access regaining going representatives the doctor providers, sell open And can increased the are begins they growth with now pack continuing over are to as channels primary are seeing trajectory First, calls. is visit. not our as growth world able a live telemedicine all patients where reach with with slowly second ANNOVERA our access that sales to trend up to their of
improved from importantly to is is from that COVID two on to alternative in uptake is method used all this QX, to including X.X while the impact long-acting force procedure-free, have the prescribers represent benefiting total in up prescriptions that the to and need. interesting from number we ANNOVERA an from or various users this their important impressive. still are of is the It’s majority market What’s creating Slide the year over the women’s, a of birth switch unmet indicating of increasingly to IUD. prescriber here within a filling a gains ANNOVERA access was we from and seeing waning This average as writer primary and ANNOVERA QX QX. segment the share two slightly of to before methods. other more the number XX, providers control new ring now of X, vaginal it recognized capturing however, Turning ANNOVERA increased methods, first being contraceptive by the never and targets prescribing. in quarter note per making and as written an ANNOVERA the there is implants penetration these challenges efforts. successful are change are number of depth prescriber is market that note Slide marketing of And XX% see that trends quarter places, and is bars On show making that sales on by coming increase
that Slide catalysts see to are continued support now potential growth ANNOVERA. moving data of ANNOVERA Turning direction. right XX, broad the near-term We as points in the uptake
Let me a few touch of on broadly. them
support. supportive. is been The women has First, in upheld around women’s choice birth Affordable increased the access environment for control Care advocacy health efforts and around Act and have
state access XX% continue ANNOVERA and to for across the not prior Second, payers. strong have coverage, have due laws. Where do we zero have we to an unrestricted the from authorization annual the pay approval majority patients at to federal currently payer ACA prescription rate all XX% dollars perspective continues of and
J-Code its fourth as that health could CMS for reimbursed the drive X early ANNOVERA and allows for receive facilities increased dispensing to live the ANNOVERA. Title own be it recommended quarter will believe in public unique This as national uptake that addition, we ANNOVERA. In market be
improving expand marketing to primary base, with access we tools providers communicate a physician to Third, is the including market utilize and to for opportunity mentioned, as continue care to broader providers ANNOVERA.
to influencer Lastly, continue on consumer will before are have positive they the what and from shaped, of than mind, they in significant impact. to in XX% Keep program and contraception friends. go doctor women want are leveraging believe often peer-to-peer And we know a their millions see of influencers have our learned women. preferences telemedicine what we front, based channel their that and they on of reach terms that more
TRx IMVEXXY $XX. cash in achieving Slide for QX I’ll of impact higher support regular filling XXXX detail the representative product X% a prescribers, for than and in the of writers withstand prescription the importantly XX Products, this quarter. IMVEXXY compared to Menopause the in for in a access XQ in VVA has outpacing growth with year supply. this second for to the of of approximately improved compared enabled total XX% XX% category XXXX first metrics market, second and over revenue writing the the of XQ rates has in for increase of we an quarter. has The a X% to price net Moving first which IMVEXXY number with pattern discuss the this net after the now quarter our increase patients X.X $XX, X, average was IMVEXXY loyalty and prescribers a January the QX more to XX, for a improvement together X% XX-day second pay fills which in Slide improved onto to increase refill And remain net shows price the a net compared in sales revenue to per the with prescriptions, unit faster a TRx shows growth COVID. lifetime for XXXX improvement moment. the of of steady the over saw changed quarter. key quarter over base There a patients
As high unit. fourth per seen revenue net this per in a net unit revenue is and a the our reminder, new improvement in we row for have quarter
coverage at there XX their as forward. only growth potential strong shows, catalysts branded XX%, Top including that that unrestricted X has near commercial Slide, As IMVEXXY IMVEXXY has product. support going a preferred strong payer IMVEXXY term are
patients with provides believe we And online increased in will amplify side, improve launched relationship consumer UpScript outreach. to And a for the access cash we to as recently continue through the program And country them up virtual is affordable support to with opens as not in vitaCare. access For an we improving noted ANNOVERA, providers patients. for those new conversion IMVEXXY on prescription covered, format, the that top telemedicine channel. to
recently direct-to-consumer engagement. impact Our a May already positive Reign showing called in Long launched is interest campaign both She and
Turning BIJUVA $XX. finally to steady notably BIJUVA increase for X.X% the revenue prescribers BIJUVA in on was for unit net at per grew Slide by compared prescriptions XQXX. writing in to XQXX prescription a total And XX, X% stayed there quarter-over-quarter,
growth addition, seven filing from now remarks. which in we it with date I BIJUVA, Rob the we quarter catalyst the closing European but resumed acceptance approval minimally to force. in over would our XX, for be been turn of our to we sampling with received of supporting field merchandising low BIJUVA countries, the like recently believe for going the received In BIJUVA will XXXX, the March dose of efforts FDA PDUFA for second And have just important both and forward.
